Channel Therapeutics Corporation: Business Overview, Financials & Competitive Analysis
Channel Therapeutics Corporation scores 4/10 on the AskCyborg Cyborg Score (Mixed). Pre-revenue clinical biotech leveraging differentiated sodium channel science for post-operative and neuropathic pain—significant market opportunity if clinical data supports regulatory approval. Clinical-stage biotech with promising non-opioid pain platform targeting high-value surgical indications, but very early-stage with limited revenue, small IPO proceeds ($6.6M in February 2024), and execution risk on.
What is Channel Therapeutics Corporation's industry? Channel Therapeutics Corporation (chromocell.com) operates in Biotechnology. AskCyborg classifies Channel Therapeutics Corporation under Biotechnology in its company registry.
Chromocell Therapeutics Corporation is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive, therapeutics to alleviate pain and other associated medical con...
Cyborg Score thesis
Pre-revenue clinical biotech leveraging differentiated sodium channel science for post-operative and neuropathic pain—significant...
Read the full analyst-debate transcript →Get the Latest Channel Therapeutics Corporation Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeChannel Therapeutics Corporation Overview
Pro stress-test →Chromocell Therapeutics Corporation is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive, therapeutics to alleviate pain and other associated medical conditions. The company changed its name to Channel Therapeutics Corporation on November 18, 2024, reflecting its strategic focus on sodium channel-based therapeutics.
Strategic Profile
Pro stress-test →The Company's initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic pain and acute eye pain. In October 2024, the company unveiled its injectable depot program utilizing peripheral nerve blocks for the treatment of post-operative pain. The company aims to address the opioid crisis with non-addictive pain therapeutics across multiple delivery modalities.
Competitive Landscape
Pro stress-test →The non-opioid pain therapeutic space includes established players like Eli Lilly (Reyvow), Vertex Pharmaceuticals (pain programs), and academic/biotech focused on CGRP, sodium channels, and selective NaV1.7 inhibitors. Channel's differentiation lies in its sodium channel modulation platform combined with novel delivery devices (sublingual, intranasal, injectable depot), targeting high-value indications including post-operative pain where unmet need and pricing power are substantial.
Industry Context
Channel Therapeutics Corporation operates in Biotechnology.
Key facts
Founded: 2002 · Headquarters: North Brunswick, New Jersey, US · Revenue: Minimal; grant revenue of $199,934 (2023); pre-revenue clinical stage